drugset / Trial / NCT01133522
Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to evaluate the safety and tolerability of multiple doses of evolocumab when given as an add-on to stable statin therapy.
Timeline
- Start
- 2010-06-01
- Primary completion
- 2011-09-14
- Completion
- 2011-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evolocumab | Monoclonal antibody | 14 mg | Subcutaneous |
| Subject | Evolocumab | Monoclonal antibody | 35 mg | Subcutaneous |
| Subject | Evolocumab | Monoclonal antibody | 140 mg | Subcutaneous |
| Subject | Evolocumab | Monoclonal antibody | 280 mg | Subcutaneous |
| Subject | Evolocumab | Monoclonal antibody | 420 mg | Subcutaneous |